Cromolyn sodium is a medication that prevents certain immune cells, called mast cells, from releasing the chemicals responsible for allergic and inflammatory reactions. Unlike antihistamines, which block symptoms after they start, cromolyn works as a preventive treatment: you take it before exposure to a trigger, and it reduces the cascade of inflammation before it begins. Originally developed for asthma, it has since found roles in treating allergic rhinitis, allergic eye disease, gastrointestinal disorders driven by mast cells, and systemic mastocytosis, with newer research exploring uses that go well beyond traditional allergy care.
How Cromolyn Stabilizes Mast Cells
Mast cells sit in tissues throughout your body, especially in places that contact the outside world: airways, nasal passages, the lining of your gut, and the conjunctiva of your eyes. When an allergen binds to antibodies on a mast cell’s surface, the cell “degranulates,” dumping histamine and other inflammatory mediators into the surrounding tissue. That dump is what triggers sneezing, wheezing, itching, swelling, and diarrhea, depending on where the mast cells live.
Cromolyn stabilizes the mast cell membrane so that degranulation either doesn’t happen or happens far less vigorously. In animal models, inhaling cromolyn before allergen exposure blocked both the early-phase airway constriction and the late-phase inflammatory response, and reduced the influx of immune cells into the airways afterward. Interestingly, when cromolyn was given after the early reaction had already resolved, it still inhibited the late-phase response and the accumulation of eosinophils, suggesting it has effects beyond simply keeping mast cells from popping open at the moment of allergen contact.1American Review of Respiratory Disease. The Effect of Cromolyn Sodium and Albuterol on Early and Late Phase Bronchoconstriction and Airway Leukocyte Infiltration after Allergen Challenge of Nonanesthetized Guinea Pigs The full scope of how it calms inflammation is still not perfectly understood, but the practical result is clear: used consistently and preventively, it damps down allergic reactions at the source.
Asthma and Exercise-Induced Breathing Problems
Cromolyn’s first and most studied use is in asthma. Inhaled before an allergen exposure or exercise session, it reduces airway narrowing and the symptoms that go with it. For exercise-induced asthma specifically, cromolyn given a few minutes before physical activity protects more than 70 percent of patients from significant airway constriction.2PubMed. The use of cromolyn in the management of hyperreactive airways and exercise That same research found cromolyn’s protection is roughly comparable to theophylline and calcium channel blockers, and better than some older alternatives, though it falls short of inhaled albuterol for immediate bronchodilation. Where cromolyn showed a particular edge was in preventing the late-phase reaction that can follow exercise-induced asthma, the second wave of breathing difficulty that sometimes hits hours later.
Head-to-head comparisons with another preventive agent, nedocromil sodium, showed both drugs worked equally well at clinically recommended doses for blocking exercise-induced asthma at 20 minutes after dosing. At the two-hour mark, however, cromolyn still provided protection while nedocromil’s effect had faded.3PubMed. The preventive effect and duration of action of nedocromil sodium and cromolyn sodium on exercise-induced asthma (EIA) in adults That somewhat longer window matters for people who need coverage through an entire gym session or sports practice.
One wrinkle worth knowing: repeated dosing before exercise can blunt cromolyn’s protective effect. A study comparing single-dose pretreatment to a 12-dose regimen found that the multi-dose approach offered less protection and accelerated recovery from lung-function dips less effectively than a single dose did.4PubMed. Attenuation of protection with repeated cromolyn dosing before exercise challenge in subjects with asthma The clinical implication is that cromolyn works best as a targeted, before-the-trigger treatment rather than something you stack up repeatedly hoping for stronger coverage.
Allergic Rhinitis
Cromolyn sodium is available as a nasal spray, sold over the counter in many countries, for seasonal allergic rhinitis (hay fever). It targets the mast cells sitting right in the nasal lining, calming the sneezing, runny nose, and congestion that come with pollen seasons. A placebo-controlled study of the nasal spray found it significantly outperformed placebo in overall allergy symptom control, sneezing relief, and nasal congestion.5PubMed. Efficacy and patient satisfaction with cromolyn sodium nasal solution in the treatment of seasonal allergic rhinitis: a placebo-controlled study Earlier multi-center work confirmed a 4 percent cromolyn solution reduced sneezing, rhinorrhea, congestion, and even eye irritation in ragweed hay fever patients.6Journal of Allergy and Clinical Immunology. Cromolyn sodium nasal solution in the prophylactic treatment of pollen-induced seasonal allergic rhinitis: A tri-city study of efficacy and safety
The catch, as with the inhaled form, is that cromolyn nasal spray has to be used consistently and started before allergy season ramps up. It is not a rescue medication. People who start spraying only once they’re already miserable tend to find it underwhelming compared to intranasal corticosteroids or antihistamines. Used as directed, though, it offers a genuinely mild side-effect profile, which makes it attractive for people who want to avoid steroid nasal sprays or who experience rebound congestion from decongestants.
Allergic Eye Disease
Cromolyn eye drops work on the same principle: stabilize the mast cells in the conjunctiva to prevent the itching, redness, tearing, and swelling of allergic conjunctivitis. A review of clinical trials found topical cromolyn effective against a range of allergic eye conditions, including seasonal conjunctivitis, chronic allergic conjunctivitis, and vernal keratoconjunctivitis, a more severe form that can affect vision. The review also noted that using cromolyn eye drops could reduce patients’ need for supplementary oral antihistamines and, more importantly, for ocular corticosteroids, sparing them from steroid-related side effects like increased eye pressure.7PubMed. Ocular sodium cromoglycate. An overview of its therapeutic efficacy in allergic eye disease
A double-masked trial comparing a preservative-free cromolyn formulation to one containing a common preservative (benzalkonium chloride) found that both improved subjective symptoms of allergic conjunctivitis and reduced clinical redness. One meaningful difference: the preservative-free version led to significantly less corneal erosion after four weeks, while the preserved version did not.8PubMed. A double-masked study to compare the efficacy and safety of topical cromolyn for the treatment of allergic conjunctivitis If you’re using cromolyn eye drops long-term, a preservative-free option is gentler on the corneal surface.
Gastrointestinal and Mast Cell Disorders
While most people associate cromolyn with the lungs, nose, and eyes, its oral form targets mast-cell-driven problems in the gut. Systemic mastocytosis, a condition where abnormal mast cells accumulate in organs throughout the body, can cause severe flushing, itching, diarrhea, abdominal pain, and even cognitive difficulties. In a crossover trial published in the New England Journal of Medicine, oral cromolyn produced marked improvement of these symptoms in 15 of 18 treatment periods, while none of the 19 placebo periods showed any benefit.9PubMed. Oral disodium cromoglycate in the treatment of systemic mastocytosis
A follow-up study with a larger group refined this picture. When gastrointestinal symptoms like diarrhea, abdominal pain, nausea, and vomiting were analyzed separately, cromolyn treatment was significantly better than placebo. For non-gastrointestinal symptoms such as skin flushing and itching, the benefit didn’t reach statistical significance.10PubMed. Cromolyn sodium in the management of systemic mastocytosis The most likely explanation is that oral cromolyn acts locally in the gut lining, where it directly contacts the overactive mast cells, while very little of it gets absorbed into the bloodstream to reach mast cells elsewhere.
Oral cromolyn has also been tried in eosinophilic gastrointestinal disorders, where an overactive immune response drives eosinophils into the gut wall. A case report documented resolution of protein-losing enteropathy and food allergy symptoms in a patient with eosinophilic gastroenteritis who was treated with oral cromolyn, with no side effects noted.11PubMed. Oral administration of cromolyn in a patient with protein-losing enteropathy, food allergy, and eosinophilic gastroenteritis A more rigorous randomized trial tested viscous oral cromolyn for eosinophilic esophagitis, a related condition. Cromolyn decreased symptom scores by about 54 percent compared to 28 percent with placebo, though it did not significantly reduce the actual eosinophil count in esophageal tissue.12Annals of Allergy, Asthma & Immunology. Viscous oral cromolyn for the treatment of eosinophilic esophagitis: A randomized, double-blind, placebo-controlled trial So patients felt better, but the underlying tissue inflammation persisted. That disconnect makes eosinophilic esophagitis one area where cromolyn’s role remains uncertain.
Mast Cell Activation Syndrome and Off-Label Dosing
Mast cell activation syndrome (MCAS) has gained attention in recent years as a diagnosis for people who experience episodic allergic-type symptoms without a clear allergic trigger: flushing, hives, GI distress, brain fog, and fatigue. Cromolyn is one of the mainstay treatments, but the standard dosing can be insufficient for some patients. A recent case series described five patients with MCAS and co-occurring chronic fatigue syndrome who benefited from high-dose oral cromolyn (1,600 to 2,400 mg per day, taken as a continuous regimen throughout the day). Those doses are well above the usual recommendations, though the authors noted they still fall within the safety limits of cromolyn’s original FDA application.13PubMed Central. A Continuous Oral Regimen of High-Dose Cromolyn Sodium Is Effective for Some Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Patients With Mast Cell Activation Syndrome Five patients is a small number, and no controlled trial has validated this approach, but it reflects a broader clinical trend: some MCAS specialists are pushing cromolyn doses higher than their predecessors typically used.
How It Compares to Inhaled Corticosteroids
If cromolyn works, why do most asthma guidelines now recommend inhaled corticosteroids (ICS) as first-line preventive therapy instead? A Cochrane systematic review pooling data from numerous trials found that ICS consistently outperformed cromolyn in both children and adults. ICS-treated patients had better lung function, fewer exacerbations (roughly one to three fewer per year depending on age group), lower symptom scores, and less need for rescue inhalers. The proportion of patients experiencing side effects, however, was similar between the two drugs.14PubMed Central. Inhaled corticosteroids versus sodium cromoglycate in children and adults with asthma
Not every study found such a clean gap. A U.S. trial comparing cromolyn to the inhaled corticosteroid triamcinolone acetonide in children with moderate asthma found both drugs provided similar and adequate control: wheezing, cough, and chest tightness decreased, and daily peak flow improved with both treatments. No significant between-group differences emerged at the doses studied.15Journal of Allergy and Clinical Immunology. Cromolyn versus triamcinolone acetonide for youngsters with moderate asthma The overall pattern, though, is that inhaled corticosteroids are more potent for most patients. Cromolyn remains a reasonable alternative for people who want to avoid steroids or who tolerate them poorly, especially in mild asthma.
The Dosing Problem
Cromolyn’s biggest practical obstacle is that it needs to be taken frequently, typically three to four times a day, and its preventive nature means skipping doses leaves you unprotected. That schedule is a hard sell. A crossover study comparing oral montelukast (taken once daily) with inhaled cromolyn (taken multiple times daily) in children with mild to moderate asthma found that 84 percent of children were highly adherent to montelukast, while only 48 percent managed the same level of adherence with cromolyn.16Current Therapeutic Research. Comparison of oral montelukast and inhaled cromolyn with respect to preference, satisfaction, and adherence: a multicenter, randomized, open-label, crossover study in children with mild to moderate persistent asthma
For young children whose parents manage their medication, the burden is even more tangible. A comparison of budesonide inhalation suspension (once or twice daily) with cromolyn nebulizer solution (three to four times daily) noted that the simpler dosing schedule decreased caregiver burden and could enhance willingness to stick with the treatment.17Pediatrics. Effects of Budesonide Inhalation Suspension Compared With Cromolyn Sodium Nebulizer Solution on Health Status and Caregiver Quality of Life in Childhood Asthma This adherence gap is probably the single biggest reason cromolyn has faded from front-line asthma treatment, even though its safety profile is excellent. A drug that doesn’t get taken can’t work.
Safety and Use During Pregnancy
Cromolyn sodium has one of the cleanest safety records of any allergy or asthma medication. It acts locally on the tissue surfaces where it is applied, and very little enters the bloodstream. In the oral form, absorption is estimated to be only about 5 percent in animal models, which is why the oral version works well in the gut but poorly for systemic symptoms.18PubMed. Oral delivery of sodium cromolyn: preliminary studies in vivo and in vitro The inhaled and topical forms similarly stay close to where they’re applied.
That low systemic exposure translates to minimal systemic side effects. Most people experience nothing worse than mild throat irritation (from the inhaler) or an unpleasant taste (from the nasal spray). A critical review of allergy medications and fetal safety classified intranasal cromolyn as a low-risk therapy during pregnancy, placing it alongside budesonide and first-generation antihistamines as options considered acceptably safe for expectant mothers who need allergy relief. For pregnant women who are cautious about any steroid use, cromolyn is often the most reassuring choice available.
Why Cromolyn Has Fallen Off the Radar
Despite its safety, cromolyn has become less familiar to newer clinicians. The proliferation of inhaled corticosteroids, long-acting bronchodilators, leukotriene receptor antagonists, and biologic therapies has crowded the asthma treatment landscape, and many younger healthcare providers simply haven’t worked with the drug as a routine option. That unfamiliarity creates a self-reinforcing cycle: doctors who never prescribe it never see it work, and so they never think to prescribe it.
The commercial picture has also shifted. In the United States, the inhaled form (Intal) was discontinued from the market, though some compounding pharmacies still prepare nebulizer solutions. The nasal spray (NasalCrom) and oral concentrate (Gastrocrom) remain available. In other countries, availability varies. If you’re specifically seeking cromolyn, you may need to ask for it by name rather than expecting a provider to suggest it unprompted.
Neuroinflammation and Cognitive Research
Some of the most intriguing recent work on cromolyn has nothing to do with allergies. Researchers have been exploring whether stabilizing brain mast cells with cromolyn can reduce neuroinflammation, the kind of immune activation in the brain that contributes to cognitive decline. In rat studies, injecting cromolyn directly into the hypothalamus before triggering systemic inflammation inhibited the activation of microglia (the brain’s resident immune cells), reduced the release of inflammatory signaling molecules, and improved performance on memory tests.19Frontiers in Cellular Neuroscience. Stabilization of Brain Mast Cells Alleviates LPS-Induced Neuroinflammation by Inhibiting Microglia Activation A separate study found that cromolyn suppressed brain mast cell degranulation, which in turn reduced microglial activation and inhibited several key inflammatory signaling pathways.20PubMed. Suppression of Brain Mast Cells Degranulation Inhibits Microglial Activation and Central Nervous System Inflammation
Another group investigated this connection in the context of post-surgical cognitive dysfunction, a recognized complication where patients (often elderly) experience confusion and memory problems after surgery. In their animal model, pre-treating with cromolyn reduced mast cell degranulation in the brain, decreased inflammatory cytokines, limited neuronal death, and improved cognitive function within 24 hours of surgery.21PubMed Central. Activated brain mast cells contribute to postoperative cognitive dysfunction by evoking microglia activation and neuronal apoptosis All of this is still in animal research territory, and the barrier of getting enough cromolyn across the blood-brain barrier in humans is a substantial one. But the results point to a mechanism that could eventually matter for neurodegenerative conditions where neuroinflammation plays a role.
New Delivery Methods
Cromolyn’s low oral bioavailability is both a feature and a limitation. It’s a feature for gut-focused conditions, since the drug stays in the GI tract where you want it. But for any condition requiring systemic absorption, that roughly 5 percent bioavailability is a problem. Researchers have been experimenting with ways to improve intestinal uptake. One approach uses proliposomal beads, tiny lipid-coated particles that spontaneously form vesicles when they encounter fluid in the gut. Studies using cell and tissue models found that these bead formulations enhanced cromolyn transport significantly compared to the free drug.22PubMed. Improved delivery of cromolyn from oral proliposomal beads
Another strategy involves encapsulating cromolyn in biodegradable polymer nanoparticles. An ex-vivo intestinal permeation study showed roughly a fourfold improvement in cromolyn absorption using this nanoparticle approach, confirmed by confocal microscopy in living animals after oral administration.23PubMed. Cromolyn sodium encapsulated PLGA nanoparticles: An attempt to improve intestinal permeation Neither technology has reached the pharmacy shelf yet, but if one of them pans out, it could open the door to using cromolyn for systemic mast cell conditions where the current oral form falls short.
Cromolyn in Veterinary Medicine
Horses with chronic obstructive pulmonary disease (often called “heaves”) suffer from an inflammatory airway condition triggered by barn dust and hay particles, conceptually similar to occupational asthma in humans. A study of five horses with confirmed COPD found that pre-treating with inhaled cromolyn before dust exposure significantly reduced the rise in airway resistance and restored breathing volume to control levels.24PubMed. Effects of cromolyn in horses with chronic obstructive pulmonary disease The same preventive logic applies: administer before the trigger, and the airways stay calmer. Cromolyn’s safety profile makes it appealing in veterinary contexts where long-term steroid use carries its own risks, particularly in horses, where corticosteroids can contribute to laminitis.